Delayed Graft Function  >>  Soliris (eculizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
PROTECT , NCT02145182 / 2013-004650-25: Prevention of Delayed Graft Function Using Eculizumab Therapy (Study)

Checkmark PROTECT
Dec 2016 - Dec 2016: PROTECT
Completed
2/3
288
Canada, US, Europe, RoW
Eculizumab, Soliris, Placebo
Alexion Pharmaceuticals, CTI Clinical Trial and Consulting Services
Delayed Graft Function
11/16
11/16

Download Options